Gyre Therapeutics
GYRE----
Gyre Therapeutics (GYRE)
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drug...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Gyre Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 5, 2026Price forecast
$18.67214.25%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jun 22 at 03:03 PM
Gyre Therapeutics COO Ye Weiguo disposes of USD 87,450 common shares
- TradingView · Jun 2 at 05:13 AM
Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress
- TradingView · May 14 at 04:33 PM
Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027
- Earnings Watch · May 8 at 03:25 PM
Gyre Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M
- Earnings Watch · May 7 at 10:24 PM
Gyre Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M
- Market Beat · May 7 at 09:15 PM
Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock
